| Followers | 1324 |
| Posts | 66548 |
| Boards Moderated | 12 |
| Alias Born | 01/24/2010 |
Monday, April 12, 2010 5:14:57 PM
My PICK from 2 Weeks AGO MIPI is back in PLAY !!
Molecular Insight Pharmaceutica
(NasdaqGM: MIPI)
After Hours: 2.26 Up 0.76 (50.67%) 4:51pm ET
4:07PM Molecular Insight Pharmas' Onalta phase 2 data published in Journal of Clinical Oncology (MIPI) 1.97 +0.46 : Co announces results from a completed Phase 2 clinical trial of Onalta (Yttrium-90 edotreotide) have been published in the Journal of Clinical Oncology. Results from the Phase 2 clinical trial of 90 patients show that treatment with Onalta improved symptoms associated with metastatic carcinoid tumors. Patients enrolled in the Phase 2 clinical study suffered from malignant metastatic carcinoid tumors and were refractory to conventional treatment with the somatostatin analogue, octreotide. Y-90-edotreotide therapy resulted in objective tumor response or stable disease in 67 (74.4%) of 90 patients with metastatic carcinoid refractory to octreotide therapy. Median progression-free survival and overall survival were 16.3 and 26.9 months, respectively. Furthermore, there appeared to be a correlation with prolongation of the period of progression free survival in those patients who had durable diarrhea improvement.
Molecular Insight Pharmaceutica
(NasdaqGM: MIPI)
After Hours: 2.26 Up 0.76 (50.67%) 4:51pm ET
4:07PM Molecular Insight Pharmas' Onalta phase 2 data published in Journal of Clinical Oncology (MIPI) 1.97 +0.46 : Co announces results from a completed Phase 2 clinical trial of Onalta (Yttrium-90 edotreotide) have been published in the Journal of Clinical Oncology. Results from the Phase 2 clinical trial of 90 patients show that treatment with Onalta improved symptoms associated with metastatic carcinoid tumors. Patients enrolled in the Phase 2 clinical study suffered from malignant metastatic carcinoid tumors and were refractory to conventional treatment with the somatostatin analogue, octreotide. Y-90-edotreotide therapy resulted in objective tumor response or stable disease in 67 (74.4%) of 90 patients with metastatic carcinoid refractory to octreotide therapy. Median progression-free survival and overall survival were 16.3 and 26.9 months, respectively. Furthermore, there appeared to be a correlation with prolongation of the period of progression free survival in those patients who had durable diarrhea improvement.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
